ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Two studies were presented during the 2020 American Society of [...]
Two small studies reported on patients whose kidney cancer had [...]
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
The combination of nivolumab with ipilimumab has been proven to [...]
In this paper, three clinical trials with immunotherapy combinations for [...]
Results from the TITAN-RCC clinical trial to assess tailored immunotherapy [...]
An interim analysis of study Checkmate 920 has shown that [...]
We are delighted to announce that the Scottish Medicines Consortium [...]
A review published in European Urology Focus looks at tools [...]